Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target

PHASE4CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Acromegaly
Interventions
DRUG

Sandostatin® LAR

Intramuscular injections, dosage based on either GH or IGF-I levels.

Trial Locations (1)

8000

Department of Endocrinology, Aarhus University Hospital, Aarhus C

All Listed Sponsors
collaborator

Aarhus University Hospital

OTHER

collaborator

Odense University Hospital

OTHER

collaborator

Herlev Hospital

OTHER

collaborator

Copenhagen University Hospital, Denmark

OTHER

collaborator

Aalborg University Hospital

OTHER

lead

University of Aarhus

OTHER

NCT01618513 - Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target | Biotech Hunter | Biotech Hunter